Prophylix Overview

  • Founded
  • 2008
  • Status
  • Acquired/​Merged
  • Employees
  • 4
  • Latest Deal Type
  • M&A

Prophylix General Information


Developer of prophylactic medicinal products designed to protect babies at risk from fetal and neonatal alloimmune thrombocytopenia. The company's prophylactic medicinal products are developed from plasma of rare donors recruited from blood banks, enabling healthcare providers to save new born babies from severe brain damage and death.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Parent Company
Primary Office
  • Forskningsparken
  • 9294 Tromsø
  • Norway
+47 905 00 000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Prophylix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 28-Jun-2019 00.000 Completed Generating Revenue
4. Later Stage VC 16-Apr-2014 00000 00.000 Completed Generating Revenue
3. Grant 03-May-2012 00.000 00000 Completed Generating Revenue
2. Early Stage VC 15-Dec-2011 $343K $866K Completed Startup
1. Early Stage VC 09-Apr-2010 $522K $522K Completed Startup
To view Prophylix’s complete valuation and funding history, request access »

Prophylix Executive Team (8)

Name Title Board Seat Contact Info
Søren Dahl Chief Executive Officer
Torgeir Vaage Ph.D Chief Financial Officer
Mette Kjaer Ph.D Chief Operating Officer & Scientific Co-Founder
Jens Kjeldsen-Kragh Ph.D Scientific Co-Founder & Chief Scientific Officer
Bjørn Skogen Ph.D Scientific Co-Founder & Senior Consultant
You’re viewing 5 of 8 executive team members. Get the full list »

Prophylix Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prophylix Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Union Seventh Framework Programme Government 000 0000 000000 0
NorInnova Invest Venture Capital Minority 000 0000 000000 0
NorInnova Technology Transfer Accelerator/Incubator Minority 000 0000 000000 0
Sarsia Seed Venture Capital Minority 000 0000 000000 0
To view Prophylix’s complete investors history, request access »